Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR

Asian Pacific Journal of Tropical Biomedicine

Volumn 6, Issue 2, 2016, Pages 159-163

  Shandiz, Seyed Ataollah Sadat ^a   Khosravani, Marjan ^b   Mohammadi, Sepideh ^c   Noorbazargan, Hassan ^d   Mirzaie, Amir ^a   Inanlou, Davoud Nouri ^e   Jalali, Mojgan Dalirsaber ^f   Jouzaghkar, Hamidreza ^a   Baghbani Arani, Fahimeh ^g   Keshavarz Pakseresht, Behta ^g  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e PASTEUR INSTITUTE OF IRAN   (Iran)

^f ISLAMIC AZAD UNIVERSITY   (Iran)

^g ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Breast cancer; Imatinib mesylate; KAI1 CD82; Metastasis; Real time PCR

Indexed keywords

CD82 ANTIGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMATINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; GAPDH GENE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IC50; KAI1 GENE; MCF 7 CELL LINE; MTT ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84958608226     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apjtb.2015.10.006     Document Type: Article

References (27)

1. Siegel R., Ma J., Zou Z.H., Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014, 64:9-29.
2. ®) in advanced breast cancer-expressing c-kit or PDGF-β: clinical activity and biological correlations. Ann Oncol 2008, 19:1713-1719.
3. Baran Y., Zencir S., Cakir Z., Ozturk E., Topcus Z. Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition. J Clin Pharm Ther 2011, 36:673-679.
4. Constance J.E., Woessner D.W., Matissek K.J., Mossalam M., Lim C.S. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Mol Pharm 2012, 9:3318-3329.
5. Blay J.Y., Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 2014, 40:242-247.
6. Bansa S. Is imatinib still the best choice as first-line oral TKI. South Asian J Cancer 2014, 3:83-86.
7. Weigel M.T., Dahmke L., Schem C., Bauerschlag D.O., Weber K., Niehoff P., et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 2010, 10:412.
8. Rosenberg A., Mathew P. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Invest Drugs 2013, 22:787-794.
9. Hassler M.R., Vedadinejad M., Flechl B., Haberler C., Preusser M., Hainfellner J.A., et al. Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springerplus 2014, 3:111.
10. Liu W.M., Zhang X.A. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett 2006, 240:183-194.
11. Jee B.K., Lee J.Y., Lim Y., Lee K.H., Jo Y.H. Effect of KAI1/CD82 on the β1 integrin maturation in highly migratory carcinoma cells. Biochem Biophys Res Commun 2007, 359:703-708.
12. Haeno H., Michor F. The evolution of tumor metastases during clonal expansion. J Theor Biol 2010, 263:30-44.
13. Bozdogan O., Yulug G., Vargel I., Cavusoglu T., Karabulut A., Karahan G., et al. Differential expression pattern of metastasis suppressor proteins in basal cell carcinoma. Int J Dermatol 2015, 54:905-915.
14. Patel B.B., He Y.A., Li X.M., Frolov A., Vanderveer L., Slater C., et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genom Proteom 2008, 5:137-149.
15. Stark A.M., Tongers K., Maass N., Mehdorn H.M., Held-Feindt J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 2005, 131:191-198.
16. Prici E., Prici A., Pătrană N., Recăreanu F., Bădulescu F., Crişan A.E., et al. Vertebral bone metastasis in breast cancer: a case report. Rom J Morphol Embryol 2011, 52:897-905.
17. Ohishi J., Aoki M., Nabeshima K., Suzumiya J., Takeuchi T., Ogose A., et al. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGF-β. BMC Cancer 2013, 13:224.
18. Saad Zaghloul M.A., Abadi A.H., Abdelaziz A.I. Functional evaluation of imatinib mesylate in hepatocellular carcinoma cells. Recent Pat Biomark 2013, 3:65-71.
19. Mehra R., Kumar-Sinha C., Shankar S., Lonigro R.J., Jing X., Philips N.E., et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011, 17:3924-3932.
20. Waning D.L., Guise T.A. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res 2014, 20:3071-3077.
21. Odintsova E., Van Niel G., Conjeaud H., Raposo G., Iwamoto R., Mekada E., et al. Metastasis suppressor tetraspanin CD82/KAI1 regulates ubiquitylation of epidermal growth factor receptor. J Boil Chem 2013, 288:26323-26334.
22. Tang Y., Bhandaru M., Cheng Y., Lu J., Li G., Ong C.J. The role of the metastasis suppressor gene KAI1 in melanoma angiogenesis. Pigment Cell Melanoma Res 2015, 28(6):696-706.
23. Malik F.A., Sanders A.J., Kayani M.A., Jiang W.G. Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion. Cancer Genom Proteom 2009, 6:205-213.
24. Zhang X.A., He B., Liu L. Requirement of the p130 CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003, 278:27319-27328.
25. Sadat Shandiz S.A., Ardestani M.S., Irani S., Shahbazzadeh D. Imatinib induces down regulation of Bcl-2 an anti-apoptotic protein in prostate cancer PC-3 cell line. Adv Stud Biol 2015, 7:17-27.
26. Weigel M.T., Meinhold-Heerlein I., Bauerschlag D., Schem C., Bauer M., Jonat W., et al. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGF beta signalling. Cancer Lett 2009, 273:70-79.
27. Fernandes B.F., Di Cesare S., Neto Belfort R., Maloney S., Martins C., Castiglione E., et al. Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma. Anal Cell Pathol (Amst) 2011, 34:123-130.